Lysca Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-11-2024
- Paid Up Capital ₹ 0.10 M
as on 07-11-2024
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 176.52%
(FY 2023)
- Profit 523.88%
(FY 2023)
- Ebitda 341.66%
(FY 2023)
- Net Worth 87.34%
(FY 2023)
- Total Assets -31.07%
(FY 2023)
About Lysca Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hitesh Vagadia, Bimal Patel, and Jitendra Suryavanshi serve as directors at the Company.
- CIN/LLPIN
U24230MH2020PTC339574
- Company No.
339574
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Apr 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lysca Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendra Suryavanshi  | Director | 24-Dec-2021 | Current |
| Hitesh Vagadia | Director | 09-Aug-2021 | Current |
Bimal Patel  | Director | 25-Jun-2020 | Current |
Financial Performance of Lysca Pharmaceuticals.
Lysca Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 176.52% increase. The company also saw a substantial improvement in profitability, with a 523.88% increase in profit. The company's net worth Soared by an impressive increase of 87.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lysca Pharmaceuticals?
Unlock access to Lysca Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lysca Pharmaceuticals?
Lysca Pharmaceuticals has a workforce of 0 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lysca Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lysca Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
